Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Specialized support and expert advice in the definition and design of preclinical studies for target validation, investigation of mechanisms of action, in vitro and in vivo pharmacodynamics and in vivo anti-inflammatory efficacy
Relevant analyses and readouts to assess the pharmacological activity of your products, covering:
clinical scoring analyses
assessment of effects at modulating of cytokine profile
effects on immune populations analyzed flow cytometry